This call focuses on resolving undiagnosed rare genetic and complex non-genetic diseases through variant validation and novel technological approaches in medical diagnostics. The call is fundamentally misaligned with Acme Corporation's strategic priorities in semiconductors, AI, photonics, space/defence, and industrial innovation—it targets healthcare and rare disease research, not deep tech or semiconductor development.
L’objectif de cet appel est de résoudre les maladies génétiques rares non diagnostiquées ainsi que les maladies rares non génétiques complexes et multifactorielles en identifiant les variants responsables chez des patients sans diagnostic moléculaire malgré des tests génétiques ou géniques a